The Hematology Podcast

Welcome to AstraZeneca's hematology podcasts where we aim to highlight important topics within hematology in discussions led by experts within the field.

Cardiovascular risk management in CLL

In this podcast series of 2 episodes you will learn more about practical implications of cardiovascular risk and manifest cardiovascular disease when treating CLL. The discussions are led by Dr Mattias Mattsson, Senior consultant in Hematology, Hematology Department, Uppsala University Hospital, Sweden.

Episode: Cardiovascular risk management in CLL from a Cardiologist’s perspective

What measures should be taken to optimize CLL treatment with consideration to cardiovascular risk factors? How important is presence, management and follow-up of atrial fibrillation and hypertension in CLL?

Welcome to listen to Dr Mattsson and Dr Manan Pareek, Fellow in cardiovascular medicine, Copenhagen University Hospital - Rigshospitalet, Denmark, discussing the importance and implications of cardiovascular risk stratification and management in chronic lymphocytic leukemia.

References: 1. Lyon, A.R., et al.European Heart Journal, 2022. 43(41): p. 4229-4361. 2. Pudil, R., Card Fail Rev. 2017 Nov; 3(2): 140–142. 3. Asteggiano, R., et al. Eur Heart J, 2020. 41(2): p. 205-206. 4. Sadler, D., et al. JACC: CardioOncology, 2020. 2(3): p. 535-538. 5. Larsson, K., et al. Br J Haematol, 2020. 190(4): p. e245-e248. 6. Zheng, H. and H. Zhan. JACC: CardioOncology, 2023. 5(1): p. 149-152. 7. Lubitz, S.A., et al. Circulation, 2022. 146(19): p. 1415-1424. 8. McDonagh, T.A., et al. Eur Heart J, 2021. 42(36): p. 3599-3726. 9. Tang, C.P.S., et al. British Journal of Haematology, 2022. 196(1): p. 70-78. 10. Quartermaine, C., et al. JACC: CardioOncology, 2023. 5(5): p. 570-590. 11. Awan, F.T., et al. Blood Advances, 2022. 6(18): p. 5516-5525. 12. Awan, F.T., et al. Blood Adv, 2019. 3(9): p. 1553-1562. 13. Hillmen, P., et al.The Lancet Oncology, 2023. 24(5): p. 535-552. 14. Capranzano, P. European Heart Journal Supplements, 2022. 24(Supplement_I): p. I54-I56. 15. Williams, B., et al. European Heart Journal, 2018. 39(33): p. 3021-3104. 16. AlAsmari, A.F., et al. Int J Mol Sci, 2022. 23(11). 17. Amitai, I., et al. Hematol Oncol, 2021. 39(2): p. 215-221.

General description of cytogenetics/diagnostics in CLL

Molecular markers are used today in clinical routine practice to identify high-risk patients with chronic lymphocytic leukemia (CLL). In this podcast series consisting of 3 episodes, you can listen to expert discussions around molecular markers that are clinically relevant to investigate in CLL patients. The discussions are led by Dr Richard Rosenquist Brandell, professor and senior physician in Clinical Genetics at Karolinska Institutet and Karolinska University Hospital in Stockholm.

Episode: Cytogenetics in CLL – The role of IGHV

Dr Rosenquist and Dr Paolo Ghia, an expert on IGHV from the Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milano, Italy, discuss the impact of IGHV status in CLL. The episode addresses questions such as; What do we mean by unmutated or mutated IGHV? How do we detect IGHV mutational status? And what is the clinical impact of IGHV mutational status for patients with CLL?

References:
1. Agathangelidis A et al. ERIC, Leukemia 2022 Aug; 36(8):1961-1968. 2. Sutton L-A et al. Haematologica 2017;102. 3. Patel K et al. J Hematol Oncol 14, 69; 2021. 4. www.ericll.org/inmunoglobin_gene_analysis

View Dr Ghia's short Q&A videos

Episode: Cytogenetics in CLL – The role of Complex Caryotype

Dr Rosenquist and Dr Panagiotis Baliakas, a true expert on complex karyotype from the Department of Clinical Genetics, Uppsala University Hospital, Sweden discuss the importance of a complex karyotype for patient management and clinical decision making in CLL. The episode addresses questions such as; What is a complex karyotype? What methods should we use to detect a complex karyotype? When to test for a complex karyotype? And what is the clinical impact of complex karyotype?

References:
1. Baliakas et al. HemaSphere, April 2022 - Volume 6 - Issue 4 - p e707. 2. Baliakaset P et al. Blood 2019; 133 (11): 1205–1216. 3. Rigolin, G.M.et al, Br J Haematol, (2018) 181: 229-233. 4. Hallek M et al. Blood 2018;131:2745–2760. 5. Chatzikonstantinou T et al. Front Oncol. 2021 Nov 29;11:788761.

View Dr Baliakas' short Q&A videos

Episode: Cytogenetics in CLL – The role of TP53

Dr Rosenquist and Dr Sarka Pavlova, an expert on TP53 aberrations, from the Masaryk University and University Hospital Brno, Brno, Czech Republic discuss one of the most important markers in CLL, TP53. The episode addresses questions such as; What do we mean with a TP53 aberration? How do we detect TP53 alterations? And what is the clinical impact of TP53 aberrations for patients with CLL?

References:
1. Malcikova J et al. Leukemia 32, 1070–1080 (2018). 2. Patel K et al. J Hematol Oncol 14, 69 (2021). 3. Pospisilova S et al. Leukemia 26, 1458–1461 (2012). 4. Malcikova et al. Leukemia 29, 877–885 (2015). 5. Olbertova H et al. BMC Cancer 22, 137 (2022). 6. Malcikova et al. Blood 2021; 138 (25): 2670–2685

Expert Answers: Dr Carsten Niemann

Why is comorbidity in CLL important to study?

CLL treatment choice - Important comorbidities to consider?

Expert answers: Dr Paolo Ghia

What is the definition of IGHV mutational status?

What is the physiological role of IGHV in a healthy person?

How do you test for IGHV and should you test it in CLL patients?

Do you from a clinical perspective consider IGHV a risk factor for CLL patients?

Expert answers: Dr Panagiotis Baliakas

What is Complex Karyotype in CLL?

When should Complex Karyotype be tested?

Can you describe the importance of Complex Karyotype in CLL patients?

Expert answers: Dr Manan Pareek

Which cardiovascular risks should be considered in CLL patients with hypertension?

Which is the optimum blood pressure level in CLL patients?

What is the best way to treat hypertension in CLL?

What is the best way to manage CV adverse event during CLL treatment?

Related content

CALQUENCE® (akalabrutinib)

Read about CLL and Calquence

Patient and information materials

Order and download materials about CLL and Calquence

Mapped Comorbidities in CLL patients

Lecture by Emelie Curovic Robtain on mapped comorbidities in CLL patients

En animasjonsfilm (3 min.), som forklarer en ny metode for å lage indirekte sammenligninger mellom studier.

How can I listen to the podcast in my preferred player?

Google Podcasts

Go to https://podcasts.google.com/ and make sure you’re signed in to your Google-account.
Copy our podcast link and press “Add by RSS Feed” in the menu.
Paste the link and press “Subscribe”.
Done!

Ta del i vår digitale kommunikasjon?

Vi merker oss at flere tenker som vi og ønsker å få kommunikasjon digitalt. Som et ledd i vår digitaliserings- og bærekraft prosess reduserer vi på AstraZeneca mengden av papir som vi sender ut med posten.

Registrer deg allerede i dag for og ikke gå glipp av våre medisinske nyheter, det seneste om våre produkter, informasjon om kurs og utdanning, pasient støtte, stipender og annen relevant informasjon som kan gjøre ditt daglige arbeid enklere. Gjør som mange av dine kolleger og ta del i informasjon når det passer deg.

Registrer deg på AstraZeneca Connect

Når du registrerer deg, får du ekstra funksjonalitet i form av at tidligere ordrer lagres og kan gjenbrukes ved ny bestilling. Dine opplysninger fylles også automatisk ut, noe som forenkler prosessen ved gjentatte bestillinger samt ved øvrig kontakt med AstraZeneca.

Registrer deg her

Allerede registrert? Logg inn her